Actively Recruiting

Phase Not Applicable
Age: 18Years +
All Genders
ID06918561

A Randomized Controlled Multisite Crossover Trial Evaluating the Efficacy of NeoThelium FT in the Treatment of "Other" Open Wounds

Led by NuScience Medical Biologics, LLC · Updated on 2026-05-06

132

Participants Needed

14

Research Sites

8 weeks

Total Duration

On this page

Sponsors

N

NuScience Medical Biologics, LLC

Lead Sponsor

S

SygNola, LLC

Collaborating Sponsor

AI-Summary

What this Trial Is About

Researchers are evaluating the effectiveness of NeoThelium FT combined with standard of care compared to standard of care alone in treating chronic open wounds. This randomized controlled crossover trial is open label, meaning both researchers and participants know which treatment is given. The study aims to collect information on wound healing and pain while supporting insurance reimbursement decisions across multiple medical centers. Participants will be randomly assigned to one of two groups: standard of care (SOC) alone or SOC plus NeoThelium FT. Those in the SOC group who do not achieve complete wound closure by about 84 days may cross over to receive NeoThelium FT along with SOC for up to 12 weekly treatments. Treatments include wound cleansing, debridement, dressings, and offloading, with NeoThelium FT being a special membrane derived from donated human placental tissue. Participants will undergo a two-week screening before randomization and then receive treatments and follow-up visits for up to 12 weeks. Assessments include measuring wound closure, wound size reduction, and pain levels at multiple time points. Researchers will monitor wound healing progress and safety throughout the study, which may last several months depending on individual response and crossover status.

CONDITIONS

Brief Title

Evaluating the Efficacy of NeoThelium FT in the Treatment of Chronic Open Wounds

Who Can Participate

Age: 18Years +
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Male or female aged 18 years or older
  • Diagnosed with "other" open wound
  • Chronic open wound present for 4 weeks or longer and less than 12 months if treated with continuous standard of care
  • Wound has shown less than 25% healing within 14 days prior to screening and randomization
  • Open wound without infection or clinically visible exposed bone
  • Wound size between 0.5 cm² and 25 cm² at first treatment
  • Wound depth no greater than 1 cm at screening
  • Offloading therapy used for wounds below the knee when applicable for at least 14 days prior to randomization
  • Adequate circulation confirmed by specific tests within 30 to 90 days prior to randomization
  • Wound free of infection and necrotic debris before treatment
  • Negative pregnancy test for women of childbearing potential
  • Ability and willingness to follow study protocol
  • Signed informed consent
  • Multiple ulcers must be at least 2 cm apart
Not Eligible

You will not qualify if you...

  • Wound diagnosed as diabetic foot, pressure, venous leg, or burn wound, or other than "open wound"
  • Life expectancy less than 1 year
  • Unable to comply with study protocol
  • Major uncontrolled medical disorders affecting wound healing
  • Active or past malignant disease or radiation at wound site
  • Conditions compromising safety per investigator
  • Contraindications to tissue-engineered allograft
  • Participation in another interfering clinical trial
  • Pregnant or breastfeeding
  • Recent immunosuppressant, chemotherapy, or topical steroid use
  • Recent treatment with tissue-engineered or scaffold wound materials
  • Active wound infection
  • Wound depth with exposed bone
  • Recent hyperbaric oxygen therapy
  • Recent revascularization surgery on wound leg
  • Suspected neoplasm at wound site

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - Up to 12 weeks for initial treatment; crossover treatment up to 12 weeks if eligible

Participants receive either standard wound care alone or standard wound care plus NeoThelium FT applications. Those initially on standard care who do not achieve wound closure by about 12 weeks may crossover to receive NeoThelium FT with standard care for up to 12 weekly treatments.

Weekly visits during treatment phase

Follow-up

Duration - Up to 12 weeks post treatment start

Participants continue follow-up assessments after treatment to monitor wound healing and pain.

Visits on Day 0, Day 14, Day 35, Day 56, and Day 84

Trial Site Locations

Total: 14 locations

1

MedCentris of Denham Springs

Denham Springs, Louisiana, United States, 70726

Actively Recruiting

2

MedCentris of Hammond

Hammond, Louisiana, United States, 70403

Actively Recruiting

3

MedCentris of Carencro

Lafayette, Louisiana, United States, 70507

Actively Recruiting

4

MedCentris of Leesville

Leesville, Louisiana, United States, 71146

Actively Recruiting

5

MedCentris of Many

Many, Louisiana, United States, 71449

Actively Recruiting

6

MedCentris of Marksville

Marksville, Louisiana, United States, 71351

Actively Recruiting

7

MedCentris of Metairie

Metairie, Louisiana, United States, 70001

Actively Recruiting

8

MedCentris of Minden

Minden, Louisiana, United States, 71055

Actively Recruiting

9

MedCentris of Slidell

Slidell, Louisiana, United States, 70458

Actively Recruiting

10

MedCentris of D'iberville

D'Iberville, Mississippi, United States, 39540

Actively Recruiting

11

MedCentris of McComb

McComb, Mississippi, United States, 39648

Actively Recruiting

12

MedCentris of Natchez

Natchez, Mississippi, United States, 39120

Completed

13

MedCentris of Southaven

Southaven, Mississippi, United States, 38671

Actively Recruiting

14

Northeast Podiatry Consultant

Brooklyn, New York, United States, 11234

Actively Recruiting

Loading map...

Research Team

A

Angelina Ferguson, DNP

S

Sarah Moore, MBE

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

RANDOMIZED

Model

CROSSOVER

Primary Purpose

TREATMENT

Number of Arms

2

Similar Trials

Phase I/IIA Open Label Study of ELU42 Topical Spray for Wagn...

Diabetic Foot Ulcer

Actively Recruiting

4 locations

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here